drugset

drugset / Trial / NCT07116889

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889 ↗

Phase 1 Active not recruiting 156 enrolled Generate Biomedicines

RandomizedSequentialDouble-blindTreatment

Summary

This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.

Timeline

Start: 2023-12-12
Primary completion: 2027-05
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GB-0895	Unknown	—	Subcutaneous

Indications